LEXEO Therapeutics LLC
New York, NY · Biotech · Public
In vivo AAV gene therapy (LEX06) delivering functional ALDH2 gene to treat ALDH2 deficiency-associated osteoporosis
- Grants
- $5.1M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Oxidation-resistant Anti-protease Therapy | $224,967 | |
| Federal grant | Department of Health and Human Services · Phase II · Oxidation-resistant Anti-protease Therapy | $1,157,532 | |
| Federal grant | Department of Health and Human Services · Phase I · Gene Therapy to Prevent Esophageal Cancer Associated with Aldehyde Dehydrogenase Deficiency | $224,970 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Gene Therapy to Prevent Esophageal Cancer Associated with Aldehyde Dehydrogenase Deficiency | $224,970 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Oxidation-resistant Anti-protease Therapy | $1,499,103 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Gene Therapy to Protect the Lung from Oxidant Stress | $224,593 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Gene Therapy to Protect the Lung from Oxidant Stress | $224,593 | |
| Federal grant | Department of Health and Human Services · Phase I · Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency | $252,042 | |
| Federal grant | Department of Health and Human Services · Phase I · Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency | $252,042 | |
| Federal grant | Department of Health and Human Services · Phase II · Oxidation-resistant Anti-protease Therapy | $341,571 | |
| Federal grant | Department of Health and Human Services · Phase I · CNS Gene Therapy for CLN2 Disease Using Parallel Multiple Routes of Administration | $499,916 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1587 | REGENERIX LLC | — | — |
| 1588 | CHEMILY, LLC | — | — |
| 1589 | REGENTIS BIOMATERIALS LTD. | — | $6.5M |
| 1590 | LEXEO Therapeutics LLC | — | — |
| 1591 | THERANOSTEC INC | — | — |
| 1592 | KURE. AI, INC. | — | — |
| 1593 | INSILICOS | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods And Pharmaceutical Compositions For The Treatment And The Prevention Of Cardiomyopathy Associated With Friedreich Ataxiaapplication
- Methods And Pharmaceutical Compositions For The Treatment And The Prevention Of Cardiomyopathy Associated With Friedreich Ataxiaapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.